Literature DB >> 23897288

IBD: Golimumab in ulcerative colitis: a 'ménage à trois' of drugs.

Silvio Danese1.   

Abstract

Golimumab, a human anti-TNF antibody, is effective in patients with ulcerative colitis, according to new findings from an international phase III double-blind trial. The addition of this drug makes a ménage à trois of available drugs--comprising infliximab, adalimumab and golimumab--for the treatment of ulcerative colitis.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23897288     DOI： 10.1038/nrgastro.2013.142

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


  7 in total

1.  A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization.

Authors:  Abderrahim Oussalah; Ludovic Evesque; David Laharie; Xavier Roblin; Gilles Boschetti; Stéphane Nancey; Jérôme Filippi; Bernard Flourié; Xavier Hebuterne; Marc-André Bigard; Laurent Peyrin-Biroulet
Journal:  Am J Gastroenterol       Date:  2010-08-24       Impact factor: 10.864

2.  Long-term outcome after infliximab for refractory ulcerative colitis.

Authors:  Marc Ferrante; Séverine Vermeire; Herma Fidder; Fabian Schnitzler; Maja Noman; Gert Van Assche; Gert De Hertogh; Ilse Hoffman; Andre D'Hoore; Kristel Van Steen; Karel Geboes; Freddy Penninckx; Paul Rutgeerts
Journal:  J Crohns Colitis       Date:  2008-05-16       Impact factor: 9.071

3.  Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.

Authors:  William J Sandborn; Paul Rutgeerts; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Jiandong Lu; Kevin Horgan; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  Gastroenterology       Date:  2009-07-28       Impact factor: 22.682

4.  Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission.

Authors:  Alessandro Armuzzi; Daniela Pugliese; Silvio Danese; Gianluca Rizzo; Carla Felice; Manuela Marzo; Gialuca Andrisani; Gionata Fiorino; Orsola Sociale; Alfredo Papa; Italo De Vitis; Gian Lodovico Rapaccini; Luisa Guidi
Journal:  Inflamm Bowel Dis       Date:  2013-04       Impact factor: 5.325

Review 5.  Review article: the role of anti-TNF in the management of ulcerative colitis -- past, present and future.

Authors:  S Danese; J-F Colombel; L Peyrin-Biroulet; P Rutgeerts; W Reinisch
Journal:  Aliment Pharmacol Ther       Date:  2013-03-13       Impact factor: 8.171

6.  Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.

Authors:  William J Sandborn; Brian G Feagan; Colleen Marano; Hongyan Zhang; Richard Strauss; Jewel Johanns; Omoniyi J Adedokun; Cynthia Guzzo; Jean-Frederic Colombel; Walter Reinisch; Peter R Gibson; Judith Collins; Gunnar Järnerot; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2013-06-14       Impact factor: 22.682

7.  Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.

Authors:  William J Sandborn; Brian G Feagan; Colleen Marano; Hongyan Zhang; Richard Strauss; Jewel Johanns; Omoniyi J Adedokun; Cynthia Guzzo; Jean-Frederic Colombel; Walter Reinisch; Peter R Gibson; Judith Collins; Gunnar Järnerot; Toshifumi Hibi; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2013-06-02       Impact factor: 22.682
  7 in total
  2 in total

Review 1.  Golimumab pharmacokinetics in ulcerative colitis: a literature review.

Authors:  Ines Harzallah; Josselin Rigaill; Nicolas Williet; Stephane Paul; Xavier Roblin
Journal:  Therap Adv Gastroenterol       Date:  2016-11-15       Impact factor: 4.409

Review 2.  Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments.

Authors:  Bruno Rafael Ramos de Mattos; Maellin Pereira Gracindo Garcia; Julia Bier Nogueira; Lisiery Negrini Paiatto; Cassia Galdino Albuquerque; Caique Lopes Souza; Luís Gustavo Romani Fernandes; Wirla Maria da Silva Cunha Tamashiro; Patricia Ucelli Simioni
Journal:  Mediators Inflamm       Date:  2015-08-03       Impact factor: 4.711
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.